While VEGF inhibition represents a valuable anticancer strategy, its cardiovascular complications, including hypertension, ventricular remodeling, and mitochondrial damage, necessitate careful monitoring and consideration of cardioprotective interventions in clinical practice. This evidence concerns the gene VEGFA and Hypertension.